Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of depemokimab in uncontrolled hypereosinophilic syndrome
MOH_2022-09-05_010688Phase 3Recruiting
- Sponsor
- GSK
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypereosinophilic syndrome (HES) comparing Depemokimab + standard of care with Placebo + standard of care (2 arms). Started Aug 2022; status: recruiting.
02
Drugs
depemokimab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on MOH_2022-09-05_010688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-09-05_010688.